Active Recombinant Human MAP3K5(649-946) Protein, N-GST,C-His-tagged

• Cat.No.: MAP3K5-25H
• Product Overview: N-Terminal GST and C-terminal 6His-tagged, recombinant, human ASK1 amino acids 649–946, expressed in E.coli cells. Purified using Ni2+/NTA agarose.

Specification

• Description: Apoptosis signal-regulating kinase 1 (ASK1) is a serine/threonine protein kinase and identified as a MAPKKK which activates the c-Jun N-terminal kinase (JNK) and p38 MAP kinase pathways and is required for TNFalpha;-induced apoptosis. ASK1 suggests possible mechanisms for redox regulation of the apoptosis signal transduction pathway as well as the effects of antioxidants against cytokine- and stress-induced apoptosis.
• Source: E. coli
• Species: Human
• Tag: GST,His
• Protein length: 649-946 aa
• Form: 3.8mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.
• Bio-activity: 52U/mg, where one unit of ASK1 activity is defined as 1nmol phosphate incorporated into 0.33mg/ml myelin basic protein (MBP) per minute at 30 centigrade with a final ATP concentration of 100μM.
• Molecular Mass: 61.5 kDa
• AA Sequence: 1 MSPILGYWKI KGLVQPTRLL LEYLEEKYEE HLYERDEGDK WRNKKFELGL EFPNLPYYID 61 GDVKLTQSMA IIRYIADKHN MLGGCPKERA EISMLEGAVL DIRYGVSRIA YSKDFETLKV 121 DFLSKLPEML KMFEDRLCHK TYLNGDHVTH PDFMLYDALD VVLYMDPMCL DAFPKLVCFK 181 KRIEAIPQID KYLKSSKYIA WPLQGWQATF GGGDHPPKSD LVPRGSPEFP GRQMVNTITE 241 EKGRSTEEGD CESDLLEYDY EYDENGDRVV LGKGTYGIVY AGRDLSNQVR IAIKEIPERD 301 SRYSQPLHEE IALHKHLKHK NIVQYLGSFS ENGFIKIFME QVPGGSLSAL LRSKWGPLKD 361 NEQTIGFYTK QILEGLKYLH DNQIVHRDIK GDNVLINTYS GVLKISDFGT SKRLAGINPC 421 TETFTGTLQY MAPEIIDKGP RGYGKAADIW SLGCTIIEMA TGKPPFYELG EPQAAMFKVG 481 MFKVHPEIPE SMSAEAKAFI LKCFEPDPDK RACANDLLVD EFLKVSSKKK KHHHHHH
• Purity: Purity 72% by SDS-PAGE and Coomassie blue staining.
• Applications: Drug Discovery & Development
• Storage: 6 months at -70 centigrade.
• Handling Advice: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into prechilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70 centigrade.
• Use/Stability: On receipt of material store at -70 centigrade. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Gene Information

• Gene Name: MAP3K5 mitogen-activated protein kinase kinase kinase 5 [ Homo sapiens (human) ]
• Official Symbol: MAP3K5
• Synonyms: MAP3K5; mitogen-activated protein kinase kinase kinase 5; ASK1; MEKK5; MAPKKK5
• Gene ID: 4217
• mRNA Refseq: NM_005923.4
• Protein Refseq: NP_005914.1
• MIM: 602448
• UniProt ID: Q99683

Reviews

06/30/2020

The MAP3K5 protein has proven to be invaluable in protein electron microscopy structure analysis.

07/24/2018

Its ability to provide accurate and reliable results in this particular application makes it a preferred choice for researchers studying antigen-antibody interactions and immune responses.

12/01/2016

The MAP3K5 protein's sensitivity and specificity ensure precise measurements, contributing to the overall success of ELISA experiments.

Q&As

What other diseases or conditions involve MAP3K5?

MAP3K5 has been implicated in various diseases, including neurodegenerative disorders, cardiovascular diseases, and inflammatory conditions.

How is MAP3K5 protein implicated in cancer?

Aberrant regulation of MAP3K5 has been associated with cancer development, as it can influence cell survival and death pathways.

Can MAP3K5 be used as a biomarker for certain diseases?

MAP3K5 expression levels and activity may serve as biomarkers for specific diseases, providing valuable information for diagnosis and prognosis.

Are there any clinical applications of MAP3K5 in cancer treatment?

Research suggests that targeting MAP3K5 could have therapeutic implications in cancer treatment, potentially through the modulation of apoptosis in cancer cells.

Are there ongoing clinical trials involving MAP3K5 inhibitors?

Investigational studies and clinical trials are underway to explore the efficacy of MAP3K5 inhibitors in different disease contexts, including cancer.